Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA9 | Q16790 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 8/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19935012 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL13785420 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL19930046 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24238614 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24824205 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24806634 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24806648 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24294505 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL21730994 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL19525536 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11110174-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210189394-A1 | Targeting Ligands For Therapeutic Compounds | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-06-24 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2020-09-24 | — | — | US | disclosed |
| US-7985406-B2 | For cellular delivery; heteropolymer containing amine containing monomer and hydrophobic monomers | ROCHE MADISON INC. (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090048410-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090023890-A1 | Membrane Active Heteropolymers | Arrowhead Pharmaceuticals, Inc. | 2009-01-22 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287628-A1 | Endosomolytic Poly(Vinyl Ether) Polymers | Arrowhead Madison Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | CYP3A4 4688/4885MAPT 3947/4885CYP2C9 4796/4885 |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | CYP3A4 4818/4885MAPT 2351/4885CYP2C9 4721/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | CYP3A4 4324/4885MAPT 2823/4885CYP2C9 4697/4885 |
| US-20210189394-A1 | Targeting Ligands For Therapeutic Compounds | FABP1, SNRPE, HAVCR2 | CYP3A4 4651/4885MAPT 3588/4885CYP2C9 4751/4885 |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | CYP3A4 4818/4885MAPT 2351/4885CYP2C9 4721/4885 |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | HAVCR2, B3GAT3, CSGALNACT1 | CYP3A4 4324/4885MAPT 2823/4885CYP2C9 4697/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | CYP3A4 4878/4885MAPT 1248/4885CYP2C9 4874/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | CYP3A4 4688/4885MAPT 3947/4885CYP2C9 4796/4885 |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | CYP3A4 4818/4885MAPT 2351/4885CYP2C9 4721/4885 |
| US-11110174-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | CYP3A4 4818/4885MAPT 2351/4885CYP2C9 4721/4885 |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | CYP3A4 4714/4885MAPT 3241/4885CYP2C9 4790/4885 |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, PCBP1, NCL | CYP3A4 4864/4885MAPT 3271/4885CYP2C9 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.